Cantor Fitzgerald Comments on Precigen FY2026 Earnings

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Precigen in a report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Kim forecasts that the biotechnology company will post earnings per share of $0.11 for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share.

A number of other research analysts have also recently commented on the stock. JMP Securities restated a "market outperform" rating and set a $6.00 price target on shares of Precigen in a research note on Thursday. Wall Street Zen cut shares of Precigen from a "hold" rating to a "sell" rating in a research note on Saturday, May 24th. Finally, HC Wainwright reiterated a "buy" rating and issued a $6.00 target price on shares of Precigen in a research note on Thursday, March 20th.

Precigen Price Performance

PGEN remained flat at $1.52 during midday trading on Wednesday. 1,253,970 shares of the company's stock were exchanged, compared to its average volume of 1,349,969. The company has a market cap of $448.67 million, a price-to-earnings ratio of -2.76 and a beta of 1.85. Precigen has a 1 year low of $0.65 and a 1 year high of $2.17. The company's 50 day moving average is $1.42 and its 200-day moving average is $1.37.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The firm had revenue of $1.34 million during the quarter, compared to analysts' expectations of $0.50 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Parkman Healthcare Partners LLC bought a new position in shares of Precigen in the 1st quarter valued at about $4,755,000. Adage Capital Partners GP L.L.C. boosted its stake in Precigen by 3.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company's stock valued at $16,801,000 after acquiring an additional 410,595 shares during the last quarter. Inspire Investing LLC acquired a new stake in Precigen during the 1st quarter worth $350,000. Nuveen LLC bought a new stake in shares of Precigen during the 1st quarter valued at $275,000. Finally, Mill Creek Capital Advisors LLC raised its position in shares of Precigen by 131.8% during the 1st quarter. Mill Creek Capital Advisors LLC now owns 255,000 shares of the biotechnology company's stock valued at $380,000 after acquiring an additional 145,000 shares during the last quarter. Institutional investors own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.